G
Gabriel N. Hortobagyi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1415
Citations - 115570
Gabriel N. Hortobagyi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 166, co-authored 1374 publications receiving 104845 citations. Previous affiliations of Gabriel N. Hortobagyi include University of Texas System & University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
Ralph O. Wallerstein,Gary Spitzer,Frank Dunphy,Susan D. Huan,Gabriel N. Hortobagyi,Jonathan C. Yau,Aman U. Buzdar,Frankie A. Holmes,Richard L. Theriault,Michael S. Ewer +9 more
TL;DR: The results indicate that high-dose MVT produces significant activity, even in heavily pretreated patients, and the morbidity and mortality from the second cycle were not greater than that for the first cycle.
Journal ArticleDOI
Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
Edgardo Rivera,Frankie A. Holmes,Aman U. Buzdar,Lina Asmar,Shu Wan Kau,Giuseppe Fraschini,Ronald S. Walters,Richard L. Theriault,Gabriel N. Hortobagyi +8 more
TL;DR: A benefit in terms of OS and DFS for patients with stage IV‐NED breast cancer who receive doxorubicin‐based adjuvant chemotherapy is demonstrated, greater on patients with node‐negative primary tumors.
Journal ArticleDOI
Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate
Christine Y. Shiang,Christine Y. Shiang,Yuan Qi,Bailiang Wang,Vladimir Lazar,Jing Wang,W. Fraser Symmans,Gabriel N. Hortobagyi,Fabrice Andre,Lajos Pusztai,Lajos Pusztai +10 more
TL;DR: Findings suggest that FGFR-1 amplification or protein overexpression in breast cancers may be an indicator for brivanib treatment, where it may have direct anti-proliferative effects in addition to its’ anti-angiogenic effects.
Journal ArticleDOI
Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy.
TL;DR: An original article on the impact of predictive and prognostic models in the setting of metastatic breast cancer is highlighted, which pioneered the use of mathematical algorithmic probability equations and biologic stratification as predictors for individual, rather than random, outcomes.
Journal ArticleDOI
Phase II study of VP16-213 (Etoposide) in refractory metastatic breast carcinoma
TL;DR: VP16-213 has significant antitumor activity in refractory breastcarcinoma and merits further evaluation.